MMP3 and SPP1 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
secreted phosphoprotein 1 |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
- Signaling by PDGF
- Integrin cell surface interactions
- Degradation of the extracellular matrix
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
MMP3 and SPOCK3 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3 |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
MMP3 and CCL7 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
chemokine (C-C motif) ligand 7 |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- Peptide ligand-binding receptors
- Chemokine receptors bind chemokines
- Class A/1 (Rhodopsin-like receptors)
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
MMP3 and BCAN |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
brevican |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
- MPS IIIB - Sanfilippo syndrome B
- Diseases of glycosylation
- Heparan sulfate/heparin (HS-GAG) metabolism
- Defective B4GALT7 causes EDS, progeroid type
- MPS I - Hurler syndrome
- MPS IX - Natowicz syndrome
- Chondroitin sulfate/dermatan sulfate metabolism
- CS/DS degradation
- Defective SLC26A2 causes chondrodysplasias
- Glycosaminoglycan metabolism
- Degradation of the extracellular matrix
- Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)
- Defective CHST14 causes EDS, musculocontractural type
- Defective PAPSS2 causes SEMD-PA
- MPS IIIA - Sanfilippo syndrome A
- Myoclonic epilepsy of Lafora
- ECM proteoglycans
- Defective CHST6 causes MCDC1
- Glycogen storage diseases
- MPS IIID - Sanfilippo syndrome D
- A tetrasaccharide linker sequence is required for GAG synthesis
- Chondroitin sulfate biosynthesis
- MPS IIIC - Sanfilippo syndrome C
- Diseases associated with glycosaminoglycan metabolism
- Mucopolysaccharidoses
- Defective EXT2 causes exostoses 2
- MPS II - Hunter syndrome
- Defective B3GAT3 causes JDSSDHD
- Defective CHST3 causes SEDCJD
- Defective EXT1 causes exostoses 1, TRPS2 and CHDS
- MPS IV - Morquio syndrome A
- Dermatan sulfate biosynthesis
- MPS IV - Morquio syndrome B
- Defective CHSY1 causes TPBS
- MPS VII - Sly syndrome
- Metabolism of carbohydrates
- MPS VI - Maroteaux-Lamy syndrome
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
MMP3 and CCL13 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
chemokine (C-C motif) ligand 13 |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
MMP3 and TNFSF11 |
matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
tumor necrosis factor (ligand) superfamily, member 11 |
- Signaling by GPCR
- EGFR Transactivation by Gastrin
- Collagen formation
- Collagen degradation
- Gastrin-CREB signalling pathway via PKC and MAPK
- Activation of Matrix Metalloproteinases
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
|
|
- Marimastat
- N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide
- 3-Methylpyridine
- A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor
- N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide
- (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine
- 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid
- Hydroxyaminovaline
- 1-Methyloxy-4-Sulfone-Benzene
- 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione
- 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide
- N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide
- R-2-{[4\'-Methoxy-(1,1\'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE
- [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID
- [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER
- 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE
- N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide
- 3-[(4\'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID
- 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER
|
|
|
|
PDE4D and APP |
phosphodiesterase 4D, cAMP-specific |
amyloid beta (A4) precursor protein |
- Signaling by GPCR
- GPCR downstream signaling
- G alpha (s) signalling events
- Opioid Signalling
- DARPP-32 events
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Adenosine monophosphate
- Dyphylline
- Ketotifen
- Iloprost
- Roflumilast
- Piclamilast
- 4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]-2-Pyrrolidinone
- 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
- 6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One
- 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- (S)-Rolipram
- Cis-4-Cyano-4-[3-(Cyclopentyloxy)-4-Methoxyphenyl]Cyclohexanecarboxylic Acid
- (R)-Rolipram
- 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- Ibudilast
- (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
- 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
- 3-ISOBUTYL-1-METHYLXANTHINE
- 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
|
|
|
|
PIM1 and APP |
Pim-1 proto-oncogene, serine/threonine kinase |
amyloid beta (A4) precursor protein |
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Adenosine monophosphate
- 3,4-Dihydroxy-1-Methylquinolin-2(1h)-One
- Staurosporine
- 2-(4-Morpholinyl)-8-Phenyl-4h-1-Benzopyran-4-One
- (3e)-3-[(4-Hydroxyphenyl)Imino]-1h-Indol-2(3h)-One
- Rbt205 Inhibitor
- Quercetin
- Phosphoaminophosphonic Acid-Adenylate Ester
- Phosphonoserine
- S,S-(2-Hydroxyethyl)Thiocysteine
- IMIDAZOPYRIDAZIN 1
- 4-(4-hydroxy-3-methylphenyl)-6-phenylpyrimidin-2(5H)-one
- (4R)-7,8-dichloro-1\',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4\'-piperidine]-4-carbonitrile
- N-phenyl-1H-pyrrolo[2,3-b]pyridin-3-amine
- (2S)-1,3-benzothiazol-2-yl{2-[(2-pyridin-3-ylethyl)amino]pyrimidin-4-yl}ethanenitrile
- (4R)-7-chloro-9-methyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4\'-piperidine]-4-carbonitrile
- 5,7-DIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE
- 6-(5-BROMO-2-HYDROXYPHENYL)-2-OXO-4-PHENYL-1,2-DIHYDROPYRIDINE-3-CARBONITRILE
- 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine
- N-cyclohexyl-3-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazin-6-amine
- 2,3-diphenyl-1H-indole-7-carboxylic acid
|
|
|
|
GSK3B and PIK3R1 |
glycogen synthase kinase 3 beta |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Metabolism of lipids and lipoproteins
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Interleukin receptor SHC signaling
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by FGFR1 mutants
- Interleukin-7 signaling
- Role of phospholipids in phagocytosis
- Phospholipid metabolism
- Fcgamma receptor (FCGR) dependent phagocytosis
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- G-protein beta:gamma signalling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- G alpha (q) signalling events
- Signaling by ERBB2
- Signaling by EGFR
- GPCR downstream signaling
- Signaling by Interleukins
- TCR signaling
- Signaling by VEGF
- GP1b-IX-V activation signalling
- Downstream signal transduction
- Signaling by FGFR mutants
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- Interleukin-2 signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- G alpha (q) signalling events
- Downstream TCR signaling
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- Synthesis of PIPs at the plasma membrane
- IRS-related events triggered by IGF1R
- G beta:gamma signalling through PI3Kgamma
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- G alpha (12/13) signalling events
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- PI Metabolism
- Innate Immune System
- Signaling by Insulin receptor
- Signalling by NGF
- Insulin receptor signalling cascade
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- NGF signalling via TRKA from the plasma membrane
- Tie2 Signaling
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell surface interactions at the vascular wall
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- GPVI-mediated activation cascade
- Interleukin receptor SHC signaling
- Signaling by FGFR1 fusion mutants
- Constitutive Signaling by EGFRvIII
- PI3K Cascade
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
- Isoproterenol
- (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
|
|
|
GSK3B and APP |
glycogen synthase kinase 3 beta |
amyloid beta (A4) precursor protein |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
GSK3B and BCL3 |
glycogen synthase kinase 3 beta |
B-cell CLL/lymphoma 3 |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
CHRNA4 and VSNL1 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
visinin-like 1 |
- Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
- Acetylcholine Binding And Downstream Events
- Postsynaptic nicotinic acetylcholine receptors
- Activation of Nicotinic Acetylcholine Receptors
- Presynaptic nicotinic acetylcholine receptors
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Highly sodium permeable acetylcholine nicotinic receptors
- Highly calcium permeable nicotinic acetylcholine receptors
- Transmission across Chemical Synapses
|
|
- Nicotine
- Butabarbital
- Butalbital
- Talbutal
- Pentobarbital
- Secobarbital
- Metharbital
- Thiopental
- Galantamine
- Primidone
- Methylphenobarbital
- Phenobarbital
- Varenicline
- Amobarbital
- Aprobarbital
- Butethal
- Heptabarbital
- Hexobarbital
- Barbital
- Barbituric acid derivative
|
|
|
|
GSK3B and PSEN1 |
glycogen synthase kinase 3 beta |
presenilin 1 |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Degradation of the extracellular matrix
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
GSK3B and BZW2 |
glycogen synthase kinase 3 beta |
basic leucine zipper and W2 domains 2 |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
DRD5 and NCS1 |
dopamine receptor D5 |
neuronal calcium sensor 1 |
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- Signaling by GPCR
- GPCR downstream signaling
- G alpha (s) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Amine ligand-binding receptors
- Metabolic disorders of biological oxidation enzymes
- GPCR ligand binding
- Dopamine receptors
|
|
- Ziprasidone
- Cabergoline
- Ropinirole
- Olanzapine
- Pramipexole
- Lisuride
- Apomorphine
- Fenoldopam
- Dopamine
- Carphenazine
- Pergolide
- Bromocriptine
- Quetiapine
- Levodopa
- Aripiprazole
- Methotrimeprazine
- Zuclopenthixol
- Rotigotine
|
|
|
|
MAPK10 and APP |
mitogen-activated protein kinase 10 |
amyloid beta (A4) precursor protein |
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- FCERI mediated MAPK activation
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- Innate Immune System
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Oxidative Stress Induced Senescence
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- MAPK targets/ Nuclear events mediated by MAP kinases
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
- Cyclohexyl-{4-[5-(3,4-Dichlorophenyl)-2-Piperidin-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine
- Cyclopropyl-{4-[5-(3,4-Dichlorophenyl)-2-[(1-Methyl)-Piperidin]-4-Yl-3-Propyl-3h-Imidazol-4-Yl]-Pyrimidin-2-Yl}Amine
- 9-(4-Hydroxyphenyl)-2,7-Phenanthroline
- Phosphoaminophosphonic Acid-Adenylate Ester
- N-(tert-butyl)-4-[5-(pyridin-2-ylamino)quinolin-3-yl]benzenesulfonamide
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide
- 4-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}-N-ethylpiperidine-1-carboxamide
- (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[(E)-2-phenylethenyl]-1H-indole-2,3-dione 3-oxime
- (3E)-5-fluoro-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-1H-indole-2,3-dione 3-oxime
- (3Z)-1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-phenyl-1H-indole-2,3-dione 3-oxime
- 5-bromo-N-(3-chloro-2-(4-(prop-2-ynyl)piperazin-1-yl)phenyl)furan-2-carboxamide
- N-cyclohexyl-4-imidazo[1,2-a]pyridin-3-yl-N-methylpyrimidin-2-amine
- N-{2\'-[(4-FLUOROPHENYL)AMINO]-4,4\'-BIPYRIDIN-2-YL}-4-METHOXYCYCLOHEXANECARBOXAMIDE
- 2-{4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]piperidin-1-yl}-N-methylacetamide
- 1-(3-BROMOPHENYL)-7-CHLORO-6-METHOXY-3,4-DIHYDROISOQUINOLINE
|
|
|
|
METAP2 and APP |
methionyl aminopeptidase 2 |
amyloid beta (A4) precursor protein |
- Inactivation, recovery and regulation of the phototransduction cascade
- Visual phototransduction
- The phototransduction cascade
- Diseases associated with visual transduction
|
- Signaling by GPCR
- Platelet degranulation
- Metabolic disorders of biological oxidation enzymes
- RIP-mediated NFkB activation via ZBP1
- Formyl peptide receptors bind formyl peptides and many other ligands
- Amyloids
- Toll Like Receptor TLR1:TLR2 Cascade
- Peptide ligand-binding receptors
- Toll Like Receptor 5 (TLR5) Cascade
- The NLRP3 inflammasome
- Gastrin-CREB signalling pathway via PKC and MAPK
- Response to elevated platelet cytosolic Ca2+
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- G alpha (i) signalling events
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- G alpha (q) signalling events
- GPCR downstream signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Platelet activation, signaling and aggregation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
- G alpha (q) signalling events
- Class A/1 (Rhodopsin-like receptors)
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- ECM proteoglycans
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Advanced glycosylation endproduct receptor signaling
- Innate Immune System
- Inflammasomes
- Cytosolic sensors of pathogen-associated DNA
- MyD88-independent cascade
- GPCR ligand binding
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- TRAF6 mediated NF-kB activation
|
- L-Methionine
- 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
- Fumagillin
- D-Methionine
- N\'-(2s,3r)-3-Amino-4-Cyclohexyl-2-Hydroxy-Butano-N-(4-Methylphenyl)Hydrazide
- (E)-(2r,3r,4s,5r)-3,4,5-Trihydroxy-2-Methoxy-8,8-Dimethyl-Non-6-Enoic Acid ((3s,6r)-6-Hydroxy-2-Oxo-Azepan-3-Yl)-Amide
- 2-Methyl-2-Propanol
- (2s,3r)-3-Amino-2-Hydroxy-5-(Ethylsulfanyl)Pentanoyl-((S)-(-)-(1-Naphthyl)Ethyl)Amide
- Ovalicin
- 5-BROMO-2-{[(4-CHLOROPHENYL)SULFONYL]AMINO}BENZOIC ACID
- 5-METHYL-2-[(PHENYLSULFONYL)AMINO]BENZOIC ACID
- 2-[(PHENYLSULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
- 2-[({2-[(1Z)-3-(DIMETHYLAMINO)PROP-1-ENYL]-4-FLUOROPHENYL}SULFONYL)AMINO]-5,6,7,8-TETRAHYDRONAPHTHALENE-1-CARBOXYLIC ACID
- N\'-((2S,3R)-3-AMINO-2-HYDROXY-5-(ISOPROPYLSULFANYL)PENTANOYL)-N-3-CHLOROBENZOYL HYDRAZIDE
- 3-ETHYL-6-{[(4-FLUOROPHENYL)SULFONYL]AMINO}-2-METHYLBENZOIC ACID
- (CHLOROACETYL)CARBAMIC ACID (3R,4S,5S,5R)-5-METHOXY-4-[(2R,3R)-2-METHYL-3-(3-METHYL-2-BUTENYL)OXIRANYL]-1-OXASPIRO[2.5]OCT-6-YL ESTER
|
|
|
|
MMP12 and PLAUR |
matrix metallopeptidase 12 (macrophage elastase) |
plasminogen activator, urokinase receptor |
- Collagen degradation
- Degradation of the extracellular matrix
|
- Post-translational protein modification
- Attachment of GPI anchor to uPAR
- Dissolution of Fibrin Clot
- Post-translational modification: synthesis of GPI-anchored proteins
|
- Acetohydroxamic Acid
- Marimastat
- CP-271485
- PF-00356231
- Batimastat
- 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
- (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
- N-(biphenyl-4-ylsulfonyl)-D-leucine
- N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
- N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
- N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
- 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
- N-oxo-2-(phenylsulfonylamino)ethanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[(4-methoxyphenyl)sulfonyl]-D-alanine
|
- Alteplase
- Urokinase
- Reteplase
- Anistreplase
- Tenecteplase
|
|
|
MMP12 and TFPI |
matrix metallopeptidase 12 (macrophage elastase) |
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) |
- Collagen degradation
- Degradation of the extracellular matrix
|
- Extrinsic Pathway
- Formation of Fibrin Clot (Clotting Cascade)
|
- Acetohydroxamic Acid
- Marimastat
- CP-271485
- PF-00356231
- Batimastat
- 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
- (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
- N-(biphenyl-4-ylsulfonyl)-D-leucine
- N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
- N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
- N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
- 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
- N-oxo-2-(phenylsulfonylamino)ethanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[(4-methoxyphenyl)sulfonyl]-D-alanine
|
- Coagulation factor VIIa
- Dalteparin
|
|
|
MMP12 and LPA |
matrix metallopeptidase 12 (macrophage elastase) |
lipoprotein, Lp(a) |
- Collagen degradation
- Degradation of the extracellular matrix
|
|
- Acetohydroxamic Acid
- Marimastat
- CP-271485
- PF-00356231
- Batimastat
- 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4\'-Ethoxy-1,1\'-Biphenyl-4-Yl)-4-Oxobutanoic Acid
- (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE
- N-(biphenyl-4-ylsulfonyl)-D-leucine
- N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE
- N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine
- N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide
- 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide
- N-oxo-2-(phenylsulfonylamino)ethanamide
- N-ISOBUTYL-N-[4-METHOXYPHENYLSULFONYL]GLYCYL HYDROXAMIC ACID
- N-[(4-methoxyphenyl)sulfonyl]-D-alanine
|
|
|
|